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There is much debate on the best management of solitary pulmonary nodules. Even if they are 
mostly benign, they may represent an early-stage lung cancer. Minimally invasive surgical removal 
is probably the best approach to this insidious disease. http://ow.ly/wMKz30nemjR
Indeterminate solitary pulmonary nodules (SPNs), measuring up to 3 cm in diameter, are incidental 
radiological findings. The ever-growing use of modern imaging has increased their detection. The 
majority of those nodules are benign; however, the possibility of diagnosing early-stage lung cancer 
still stands. Guidelines for the management of SPNs have never been validated in prospective 
comparative studies.
Positron emission tomography (PET) is a useful tool to provide functional information on SPNs. 
However, overall sensitivity and specificity of PET in detecting malignant SPNs of at least 10 mm in 
diameter are about 90% and false-negative results are reported. The development of video-assisted 
thoracic surgery has provided minimally invasive diagnosis and treatment of SPNs. In our series, 
105 patients underwent surgery based on combined increased 18F-labelled 2-fluoro-2-deoxy-d-
glucose (FDG) uptake on PET computed tomography and radiological features (morphology and 
density) without prior histological confirmation. We detected 26 false negatives (24.8%) and only 
nine false positives (8.57%). Therefore, our minimally invasive surgical approach prevented 25% 
of patients with lung cancer from a delayed treatment versus only 9% undergoing “overtreatment”.
In our monocentric cohort, patients with SPNs with large diameter, irregular outline, no 
calcifications, central location, increased FDG uptake and/or subsolid aspect benefited from a 
primary surgical resection.
Cite as: Elia S, Loprete S, 
De Stefano A, et al. Does 
aggressive management of 
solitary pulmonary nodules 
pay off? Breathe 2019; 15: 
15–23.
Review
Does aggressive management 
of solitary pulmonary 
nodules pay off?
Introduction
Pulmonary nodules can be incidental findings in 
scans performed for various indications, including 
lung cancer screening. Every year, millions of patients 
are randomly diagnosed with solitary pulmonary 
nodules (SPNs) on chest imaging or other studies 
(e.g. computed tomography (CT) urogram, cardiac 
CT, etc.) and the number is expected to increase in 
the future with the wider implementation of lung 
cancer low-dose CT screening worldwide [1–3].
The need for a systematic approach to these 
incidental cases overloads the multidisciplinary 
team, in which radiologists, thoracic surgeons, 
respiratory physicians, pathologists, palliative 
care physicians, intensive care specialists, medical 
and clinical oncologists, clinical nurse specialists 
and rehabilitation staff are involved. Recently, 
an increase in SPNs has been identified by high-
resolution CT in routine clinics, particularly in 
lung cancer screening for high-risk populations. 
Most SPNs are benign and their risk for cancer 
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increases with size, although it is hard to confidently 
differentiate small malignant pulmonary nodules 
from benign ones by CT features only. Lung cancer 
probability for nodules measuring 5–6 mm is 
0.9%, while for nodules measuring 10–15 mm it is 
11.1% [4]. Patients are usually concerned whether an 
SPN may represent an early-stage lung cancer and, 
over time, it has become challenging for clinicians to 
determine whether a nodule is cancerous at its first 
radiological detection [5]. Therefore, histopathological 
diagnoses become the vital step in the management 
of pulmonary nodules, since prompt diagnosis and 
appropriate management of early lung cancer 
presenting as an SPN has the highest cure rates, 
with 5-year survival rate for stage IA reaching up to 
80% [6]. Patients with SPNs are usually asymptomatic 
and the task for clinicians remains to decide about 
further management (surveillance or further 
diagnostics) and review whether surgical resection 
is indicated, while ensuring the patients are offered 
balanced information to reach an informed decision. 
However, the development of video-assisted thoracic 
surgery (VATS) in the past 15 years currently provides 
a minimally invasive strategy for both diagnostic and 
therapeutic excision of SPNs.
Definition criteria for SPNs
An SPN is usually defined as a rounded or 
asymmetrical opacity, well or barely demarcated, 
with a maximum diameter of 3 cm. SPNs are 
surrounded by normal or emphysematous 
lung and are not associated with atelectasis, 
lymphadenopathy or pleural changes, and they do 
not exhibit features that can be evidently associated 
with a benign disease. Lung lesions >3 cm are 
classified as masses, while lesions ≤3 mm are 
generally referred to as micronodules [7, 8].
Possible malignant and benign conditions that 
may determine the presence of indeterminate lung 
nodules are listed in table 1.
The management of SPNs depends heavily 
on the probability of malignancy. Al-Ameri et al. 
[9] published a validation study on four different 
prediction models of malignancy in pulmonary 
nodules and demonstrated that even the best 
among them had the tendency to underestimate 
the risk in subsequently confirmed malignant 
nodules, with a mean estimated probability of 
malignancy of only 34.9%.
Lung cancer is the main cause of cancer death 
among males; therefore, an SPN must be considered 
a potential lung cancer until proven otherwise, to 
avoid delaying treatment of potentially curable 
early-stage malignancy. However, overemphasising 
potential malignancy may also lead to unnecessary 
costs and patient stress. Additionally, the presence 
of malignancy depends on both patient risk (age, 
smoking history, underlying tobacco-associated 
lung disease, exposure to respiratory carcinogens, 
and other variables) and nodule characteristics. 
Therefore, the management of SPNs is influenced 
by different factors, such as the patient’s likelihood 
of lung cancer (pre-test probability), comorbidities, 
expertise and institutional cultural preferences.
The ideal approach for assessing pulmonary 
nodules is still vague, since most published 
guidelines do not clearly state which strategy is 
accompanied by high-quality evidence among 
the three that are usually considered: surveillance, 
non-surgical biopsy and surgical resection.
Table 1 Aetiology of solitary pulmonary nodules
Type Aetiology
Infectious Tuberculosis 
Atypical mycobacteria 
Fungal (histoplasmosis, coccidioidomycosis, 
cryptococcosis) 
Parasitic 
Nocardia 
Measles 
Pneumocystis jirovecii 
Round pneumonia 
Lung abscess 
Septic embolism 
Infected bulla
Neoplastic  
benign
Pulmonary hamartoma 
Benign mesenchymal tumours (lipoma, fibroma, 
chondroma, haemangioma, leiomyoma) 
Neural tumours (schwannoma, neurofibroma, 
paraganglioma) 
Sclerosing pneumocytoma 
Plasma cell granuloma 
Endometriosis
Neoplastic 
malignant
Lung cancer 
Neuroendocrine tumours (well differentiated, 
moderately differentiated, and poorly differentiated) 
Metastasis 
Malignant teratoma
Vascular Haematoma 
Arteriovenous malformation 
Pulmonary artery aneurysm 
Pulmonary venous varix 
Lung infarct
Congenital Bronchogenic cyst 
Lung sequestration
Inflammatory Rheumatoid nodules 
Sarcoidosis 
Granulomatosis with polyangiitis 
Microscopic polyangiitis
Miscellaneous Round atelectasis 
Lipoid pneumonia 
Amyloidosis 
Mucoid impaction 
Focal scar
Lymphatic Intrapulmonary lymph node 
Lymphoma
Reproduced and modified from [8] with permission.
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Diagnostics for SPNs
Imaging
The reported incidence of SPNs on chest 
radiography ranges from 0.09% to 7% [8, 10]. 
The detection rates have been improved in recent 
years by the extensive use of CT imaging, thanks 
to its higher spatial resolution, which can visualise 
nodules of 1–2 mm in diameter on thin-section 
scans. Although the clinical relevance of these 
nodules is quite different from that of larger nodules 
detected on chest radiographs, the increasing use of 
CT scans for various indications will result in almost 
1.5 million patients with incidentally detected 
lung nodules annually, which is going to represent 
a common clinical problem independent of lung 
cancer screening [8]. Rates of missed detection of 
lung cancer on chest radiography range from 20% 
to 85%, with smaller, lower attenuation (subsolid) 
nodules accounting for the majority of them. CT has 
replaced this technique and is currently the standard 
imaging procedure to detect and characterise 
SPNs. All chest CT scans in adults should be 
reconstructed and archived with contiguous thin 
sections (≤1.5 mm, typically 1.0 mm) to enable 
accurate characterisation and measurement of 
small pulmonary nodules. Routine acquisition 
and archiving of off-axis (coronal and sagittal) 
reconstructed series is strongly recommended as 
well [11].
The attenuation and morphological features of 
lung nodules on CT are crucial to determine the 
likelihood of malignancy. Qualitative assessment of 
nodule CT attenuation measured in the Hounsfield 
Unit (HU) scale has turned out to be an essential 
feature of SPNs that influences the probability of 
malignancy. The presence of calcifications is usually 
a sign of benign disease, especially when they are 
symmetrically distributed, even though they have 
been reported in all histologies of lung cancer [12].
Lung nodule attenuation may be solid or 
subsolid. Therefore, there are completely nonsolid 
or ground-glass nodules (GGNs) with a central 
blurred denseness with normal parenchymal 
features, or solid nodules with uniform soft-tissue 
attenuation that replaces lung structure. A subsolid 
nodule has both characteristics and is rarer but has 
the highest probability of malignancy, while pure 
GGNs that persist over sequential examinations are 
highly suspicious for adenocarcinoma [12]. Current 
practice suggests surveillance for pure ground-glass 
lesions detected by thin-slice collimation >3 mm 
and resection or tissue biopsy only if the lesion 
develops a solid component >5 mm [13].
Lung nodule margins may be poorly defined 
or smooth, lobulated, or spiculated. Spiculated 
margins are highly associated with malignancy 
with up to a 90% positive predictive value [13, 
14]. Lobulated margins, even though they are 
usually associated with benign disease (e.g. 
hamartoma), carry a higher positive predictive value 
for well-differentiated neuroendocrine tumours. 
Nodules with poorly demarcated margins are 
common to both non-malignant and malignant 
pathology. Less-differentiating features include 
the sunburst appearance (corona radiata), upper 
lobe location, cavitation, vessel sign and pleural 
tag [14, 15].
The evolutionary features of a subsolid nodule 
detected during follow-up on CT help in defining 
its malignant potential. The evolution over time 
of SPNs is monitored by calculating the volume 
doubling time measured with nodule volumetry 
using computer-assisted software programs. Stable 
size for at least 2 years has long been accepted 
as confirmation of benignity, while the majority 
of primary lung cancers demonstrate a doubling 
time of <400 days. Pure GGNs may have very long 
doubling times; therefore, a minimum 3-year 
follow-up is required to detect significant change 
[12]. In subsolid nodules (pure GGNs or partially 
solid nodules), since attenuation rather than size 
may anticipate malignant evolution, the assessment 
of the nodule mass (volume×CT value) has been 
recently introduced [16].
Dual-energy CT with virtually constructed 
unenhanced imaging techniques has been 
recently applied and results in a higher sensitivity 
(92%) and accuracy (82%) in pulmonary nodule 
characterisation than traditional contrast 
enhancement (sensitivity 72%, accuracy 71%), with 
the same specificity and lower radiation exposure 
[17]. Magnetic resonance imaging indications in 
thoracic assessment are limited by the low signal-
to-noise ratios within the aerated lung parenchyma, 
as well as by imaging artefacts related to cardiac 
and respiratory motion.
Metabolic imaging using 18F-labelled 2-fluoro-
2-deoxy-d-glucose (FDG) positron emission 
tomography (PET) is a useful tool to provide 
functional information on SPNs with a minimum 
diameter of 8 mm that cannot be achieved by 
anatomical cross-sectional imaging alone [18]. 
The overall sensitivity and specificity of PET in 
detecting malignant SPNs with a diameter of 
≥10 mm is about 90%, yet false-negative results 
are reported in subsolid nodules such as low-grade 
neuroendocrine neoplasms (carcinoid tumours) 
and mucinous adenocarcinomas [19, 20]. When 
combined with CT (fusion PET-CT) it results in a more 
accurate characterisation of the nodule and a higher 
specificity [21]. Moreover, the combination of PET-CT 
with pre-test clinical risk assessment can better 
detect the prediction of malignancy, as shown by 
Herder et al. [22]. Yi et al. [23] reported that PET-CT 
was more sensitive (96% versus 81%) and accurate 
(93% versus 85%) than helical dynamic CT alone. 
The recent guidelines from the Fleischner Society 
recommend the use of PET-CT in the evaluation 
of ≥8 mm solid SPNs in both low- and high-risk 
patients, although the average risk of malignancy 
in an 8-mm SPN is about 3% [11]. However, in a 
study by Nomori et al. [18], 90% of GGNs, finally 
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diagnosed as well-differentiated adenocarcinomas, 
had a low metabolic uptake. Similarly, inflammatory 
nodules commonly present as ground-glass or 
subsolid attenuation, are often metabolically active, 
and lead to false-positive results [24].
The recently developed four-dimensional 
PET-CT, or respiratory-gated PET-CT, reduces image 
misregistration and corrects for respiratory motion, 
thus improving the assessment of metabolic activity 
of the nodule. This technique is useful in evaluating 
nodules located adjacent to the diaphragm, since 
it reduces the influence of motion on reading the 
FDG uptake [25].
Quantitative image analysis, also named radiomics, 
is based on the principle that the biomedical images 
contain information on tumour phenotype that can 
be correlated with clinical and molecular data to clarify 
the presence of malignancy [26]. Such an emerging 
field continues to grow but requires a multidisciplinary 
approach to provide reliable data.
Tissue sampling techniques
Cytological and/or histological diagnosis is the 
gold standard in definition of SPNs, although less 
invasive techniques such as liquid biopsy or analysis 
of exhaled breath for volatile organic compounds 
are on the increase. Several sampling techniques 
and methods are currently available, each with 
strengths and weaknesses. The choice must be 
made with due consideration of the patient’s status, 
risk of complications, nodule characteristics and 
institutional expertise.
Contemporary endobronchial techniques are 
being implemented for tissue sampling, such as radial 
probe endobronchial ultrasound, virtual navigational 
bronchoscopy and electromagnetic navigational 
bronchoscopy, although percutaneous image-guided 
transthoracic biopsy still remains a crucial minimally 
invasive technique to obtain diagnostic tissue.
Cytology on fine-needle aspiration biopsy (FNAB) 
is inadequate for definitive benign diagnosis, 
while core biopsy provides histological samples 
with diagnostic accuracy rates for malignancy of 
between 90% and 95%. Pneumothorax (8–30%) 
and haemorrhage (4–27%) are the most common 
complications of transthoracic FNAB, sometimes 
requiring chest drainage (1–15%) [27].
Therapeutic modalities for 
SPNs
There are several evidence-based recommendations 
from scientific societies for methodical approaches 
to managing SPNs [11, 27–29]. Nevertheless, 
none of these guidelines has been well validated 
in prospective comparative effectiveness studies. 
All guidelines take into due consideration multiple 
factors that may influence decision-making, such 
as clinical risk, nodule morpho-volumetric features, 
imaging evolution during surveillance, need for 
histological diagnosis, risk of complications, 
comorbidities, and risk of surgical resection.
The recommendations of the Fleischner Society 
and the American College of Chest Physicians (ACCP) 
apply to patients with incidentally detected SPNs, 
yet are based on studies offering relatively limited-
quality evidence [11, 30]. The American College 
of Radiology recommendations for surveillance 
are even less intensive than for incidentally 
detected nodules [29]. The British Thoracic Society 
guidelines recommend no nodule follow-up when 
the morphology is clearly suggestive of benign 
disease, for nodules of <5 mm in diameter and 
for perifissural or subpleural nodules of <10 mm 
diameter [28]. Conversely, the ACCP suggests CT 
surveillance for nodules <8 mm in diameter, or for 
those with a malignant risk of ≤5% [30].
Management of SPNs is a constantly evolving 
field that matches the improvement of medical 
culture, technology and expertise. Any strategy 
concerning SPNs has to consider the likelihood of 
clinically significant malignancy. Several features 
contribute to assessment of the risk for malignancy 
of SPNs: size, attenuation, morphology and location.
The vigorous development of thoracic surgery 
over the past 20 years, with the routine use of VATS 
techniques, provides a minimally invasive strategy 
for diagnostic or therapeutic excision of SPNs. 
Therefore, minimally invasive surgical resection 
is currently the treatment of choice for nodules 
with significant probability of malignancy based 
on clinical and imaging investigations, or when 
diagnosis is achieved by means of transthoracic 
FNAB as recommended by most guidelines. The 
surgical resection of SPNs without histological 
diagnosis is still a matter of debate.
Determining nodule localisation has been 
performed through a variety of techniques, aiming 
to provide the best aid in video-assisted surgical 
resection of nodules <2 cm in diameter, but without 
any evidence of superiority for a specific technique. 
Two studies compared surgical resection with or 
without pre-operative diagnosis [31, 32], but both 
were non-randomised and presented quite a few 
limitations and bias that prevented drawing any 
significant conclusions. Many studies have addressed 
the surgical approach (VATS or open lobectomy) 
and the extent of resection (lobectomy versus 
segmentectomy or wedge) for nodules diagnosed 
as malignant, but none has dealt with the specific 
problem of SPNs. Patients undergoing VATS resection 
have significantly lower rates of post-operative 
complications and in-hospital mortality when 
compared to those undergoing thoracotomy, with no 
significant difference in 3-year overall survival [33].
As far as the extent of resection is concerned, 
some studies have demonstrated inferiority of wedge 
resection compared to segmentectomy, while quite 
a few non-randomised studies have demonstrated 
equivalence in the oncological outcomes of lobectomy 
versus segmentectomy, especially for tumours <20 mm, 
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but better outcomes with lobectomy for larger cancers, 
as reported in a recent meta-analysis [34]. Lobectomy 
remains the most widely adopted treatment of nodules 
with a diagnosis of lung cancer achieved either pre-
operatively or intra-operatively. When intra-operative 
frozen section confirms malignancy, resection should 
be extended for completion lobectomy if previous 
pulmonary function testing allows an extended 
procedure. Anatomical video-assisted segmentectomy 
is the alternative for poorly performing patients, or when 
location of the nodule precludes a wedge resection and 
subsequent frozen section [35].
The onset and progressive implementation 
of awake thoracoscopic surgery has given the 
go-ahead to multiple surgical procedures in non-
intubated patients, thus minimising the patient’s 
discomfort, reducing the complication rate due to 
general anaesthesia and shortening the length of 
hospital stay [36, 37]. When the operative risk is too 
high for the patient to undergo general anaesthesia, 
awake video-assisted wedge resection represents 
a valid surgical alternative strategy [38, 39]. 
Stereotactic ablative radiotherapy or other ablative 
techniques such as radiofrequency or microwave 
ablation, for which no superiority compared to 
surgery has ever been demonstrated, represent in 
our opinion a less favourable route, to be considered 
as an alternative only in relevant cases of informed 
patient choice against surgery or comorbidities 
precluding surgery [40].
The optimal management approach of nonsolid 
or partially solid nodules, or GGNs, has been a 
matter of debate. The management of subsolid 
pulmonary nodules remains controversial, as there 
are fewer available historical data to form evidence-
based guidelines. Frequently, these nodules are 
histologically proven to be minimally invasive 
adenocarcinoma, adenocarcinoma in situ or atypical 
adenomatous hyperplasia, and this is mainly based 
on the presence of specific clinical (patient’s age) 
and radiological features (nodule size, bubble-like 
appearance and pleural retraction or indentation) 
[41, 42]. In general, the development of a solid 
component in a previously pure GGN and the increase 
in size of the solid component of a subsolid nodule 
or partially solid nodule over follow-up is predictive 
of malignancy [43]. Based on surgical outcome and 
long-term survival reported after surgery for such 
cases, most guidelines recommend surgical resection 
when surgical risk, comorbidities and effect on life 
expectancy have been thoroughly discussed.
Existing guidelines for SPN 
management
Clinical management of incidental pulmonary 
nodules was previously based on a Fleischner 
Society statement published in 2005 [44]. This 
was the main reference document until 2013, and 
since then three new guidelines and one statement 
have emerged, presenting up-to-date evidence 
that has changed practice [11, 28, 30, 45]. Table 2 
presents the three up-to-date guidelines issued 
by relevant societies.
Although these guidelines are particularly helpful, 
they need to be adopted into the national standards 
and available resources of each country where they 
are implemented. It seems that these guidelines 
differ in their recommendations and this could 
potentially cause confusion and variation in clinical 
practice among various centres, rather than achieving 
a single uniform approach. The detailed description 
of all the aforementioned guidelines is beyond the 
scope of this article; however, we would like to 
highlight that these pulmonary nodule guidelines 
share some common ground, such as nodule size/
consistency and risk assessment. The actual baseline 
and repeat protocols, as well as the size cut-off, 
differ among them. The size threshold to exclude 
patients from further follow-up is 5 mm for the ACCP 
and British Thoracic Society guidelines, and 6 mm 
for those from the Fleischner Society. This 1-mm 
difference could potentially have a major impact on 
resources in big centres with well-established nodule 
services and it would be very interesting to calculate 
in such clinical settings how many scans and how 
much clinician time would be saved. Nodules are 
further classified into solid and subsolid (pure GGN 
or partially solid) according to their consistency and 
this is an important classification for all guidelines to 
determine further diagnostic work-up or surveillance.
However, further work-up, surveillance and 
decision-making processes are influenced by 
factors at the systems level, physician level and 
patient level [46]. From a systems perspective, 
local resources are important, as many institutions 
may lack the infrastructure and resources to ensure 
multidisciplinary evaluation, or patient databases to 
ensure they are not lost to follow-up [47]. Physician 
experience also plays a crucial role in the process, 
as do patient choice and comorbidities, which need 
to be taken into account. In the next section, we 
share some real-life data on SPNs based on our 
institutional approach in patients with incidental 
SPNs that underwent surgical resection.
Real-life data on SPNs
Hypothesis
Patients with suspicious incidental SPNs and 
appropriate multidisciplinary evaluation can safely 
undergo surgical resection without prior histological 
confirmation.
Table 2 Current guidelines for the management of incidental pulmonary nodules
Society Year Reference
American College of Chest Physicians 2013 [30]
British Thoracic Society 2015 [28]
Fleischner Society 2017 [11]
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Patients and methods
Our institutional experience concerns a preliminary 
subset of 105 consecutive patients with SPNs (63 
males, 42 females; median (range) age 68 (44–
86) years) who had undergone PET-CT and surgical 
resection between January 2016 and December 
2017. Only SPNs <3 cm in diameter within a pattern 
of normal lung tissue were included. The presence 
of lymphadenopathy, pleural effusion, radiological 
features clearly suggesting malignancy or benign 
disease, and previous cytological diagnosis, were 
considered as exclusion criteria.
All patients were discussed within our Thoracic 
Oncology Working Group led by a thoracic surgeon 
and composed of a representative from each 
of the departments of respiratory, medical and 
clinical oncology, radiology, pathology and nuclear 
medicine.
All patients with a maximum standard uptake 
value (SUVmax) >2.5 or those with SUVmax <2.5 and 
morphological as well as densitometric features 
suggesting possible malignancy (spiculated 
margins, pleural retraction, pleural tag, bronchus 
sign, attenuation value >15 HU) underwent 
video-assisted wedge resection with frozen 
section examination. Intra-operative diagnosis of 
malignancy would indicate completion uniportal 
video-assisted lobectomy within the same 
procedure if the patient had been considered fit in 
the pre-operative work-up.
Results
No major surgical complications were recorded 
except for three (2.8%) prolonged air leaks that 
required a Heimlich valve in the post-operative 
period that was removed at 12 days (one patient) 
or 14 days (two patients), and five (4.7%) with 
exacerbated post-operative pain requiring prolonged 
administration of intravenous paracetamol. In this 
cohort, we detected 26 (24.8%) false negatives, 
who were essentially the patients who would not 
be referred for surgery even after a subsequent 
short-term follow-up (figure 1). Conversely, we 
found only nine (8.57%) false-positive cases, who 
were undoubtedly candidates for surgical resection 
according to current guidelines for both SUVmax 
values and morphodensitometric features.
Histology showed primary lung cancer in 76 
(72.3%) patients, metastatic cancer in 10 (9.5%), 
six (6.6%) carcinoids and benign disease in 13 
(12.3%) cases. Primary adenocarcinoma was the 
predominant histology (n=51, 67.1%), followed 
by squamous (n=13, 17.1%), neuroendocrine 
tumours (n=11, 14.4%) and small cell (n=1, 1.3%). 
Interestingly, although not statistically relevant 
due to the small number of patients enrolled up 
to now, the subsolid aspect was more associated 
with malignancy than solid nodules (93% versus 
84%), even when the latter were characterised 
by greater SUVmax values (table 3). All patients 
underwent a minimally invasive uniportal procedure 
(thoracoscopic video-assisted wedge resection), 
thanks to the availability of frozen section procedures 
within the operating theatre, thus avoiding any major 
post-operative complications. Completion uniportal 
lobectomy was performed in 65 (79.2%) patients, 
while in 17 patients conversion to a muscle-sparing 
thoracotomy was required (conversion rate 20.7%), 
due to severe fibrosis around bronchus or vessels in 
nine (52.9%) cases, intra-operative vascular injury 
and uncontrolled bleeding in four (23.5%), thick 
pleural adhesion in two (11.7%), and fused interlobar 
a) b)
Figure 1 Pulmonary atypical carcinoid of the right lower lobe. a) CT scan showing a polylobate nodule of 15 mm in diam-
eter. b) The same nodule on PET scan, with SUVmax 1.27 (cut-off 2.5).
Table 3 Nodule aspect and malignancy
Aspect Samples SUVmax >2.5 SUVmax <2.5 Malignant nodules Benign nodules
Solid 64 48 (75%) 16 (25%) 54 (84%) 10 (16%)
Subsolid 41 29 (71%) 12 (29%) 38 (93%)  3 (7%)
Data are presented as n or n (%). Subsolid aspect was more associated with malignancy than solid 
nodules, even when the latter were characterised by greater SUVmax values.
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fissure in two (11.7%). The 30-day post-operative 
mortality was zero, while the complication rate was 
only 2.8% (prolonged air leak in three cases that 
required a Heimlich valve, removed in outpatient 
clinic 12–14 days post-operatively). The mean±sd 
length of post-operative stay was 3.72±1.33 days 
(range 2–8).
Discussion
SPNs are a diagnostic and therapeutic challenge. 
Differentiation of malignant from benign lung 
nodules is a primary concern of lung cancer 
multidisciplinary teams. Although such lesions 
are usually benign, the risk of malignancy 
remains significant. This is true for both lung 
and metastatic cancer, since surgical resection 
is the only modality currently offering increased 
chances of cure and is considered the treatment 
of choice. In previously reported studies, including 
the Dutch–Belgian randomised lung cancer 
screening trial (Nederlands–Leuvens Longkanker 
Screenings Onderzoek (NELSON)), more than 
20% of participants who underwent low-dose CT 
screening required a repeat CT, PET imaging, or 
a biopsy procedure within 12 months after their 
first screening low-dose CT because of suspicious 
or intermediate lung nodules. The NELSON trial 
is the largest European trial, having randomised 
15 822 subjects. It is powered at 80% to show a 
lung cancer mortality reduction of at least 25%, 
10 years after randomisation [48]. Although in 
approximately 25% of the surgical procedures the 
nodule was determined to be benign, we believe 
that VATS has revolutionised the surgical approach 
by significantly reducing the surgical trauma, the 
length of hospital stay, post-operative pain and 
complications, and the duration of recovery of full 
activity.
The number of patients with SPNs undergoing 
PET-CT is constantly growing, due to the wider 
implementation of guidelines and pathways 
aiming at detecting lung cancer as early as possible 
to ensure these patients maximise their chance 
of cure. The management of SPNs is widely 
dictated by currently available guidelines that 
relate radiological follow-up and risk stratification 
from low to moderate to high [11]. PET-CT is a 
noninvasive and highly precise procedure to 
characterise SPNs with a reported sensitivity of 
up to 96–97% and a specificity of 85–88% [15]. 
PET-CT plays a crucial role in differentiating 
nodules >1 cm but, for those <1 cm, in single 
metastases in some types of malignancies or in 
benign diseases with increased FDG uptake, it 
is not conclusive [18, 24]. For nodules >8 mm, 
radiological imaging (CT and PET-CT) is usually 
accompanied by FNAB and even nodule resection. 
Therefore, PET-CT complements the clinical 
and diagnostic evaluation of the patient and a 
careful radiological analysis of the morphological 
characteristics of the nodule is required, as 
demonstrated in our series of patients [49].
Conclusions
The accurate assessment of risk before additional 
imaging and volumetric analysis has an important 
place in lung cancer screening. In the presence 
of an indeterminate SPN characterised by 
large diameter, irregular outline, absence of 
calcifications, central location, increased FDG 
uptake and subsolid aspect, a surgical resection 
should be offered. In these cases, where the SUVmax 
is not elevated but morphology is suspicious for 
malignancy, the possibility of implementing video-
assisted minimally invasive surgical excision and 
frozen section examination in the operating setting 
helps us in detecting malignancy at an early stage 
and improves our patients’ survival and quality 
of life.
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Self-evaluation questions
1. What is the definition of an SPN?
2. Which is the standard imaging technique to detect an SPN?
3. What are the crucial elements to determine the likelihood of 
malignancy of an SPN?
4. Which is the most widely adopted treatment of nodules with a 
diagnosis of lung cancer?
5. What is the NELSON trial?
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